Comparison of definitive chemoradiotherapy and surgical results in local advanced (stage IIIa and IIIb) non-small cell lung cancer: single-center experience
Abstract
Objective: Discussions regarding the treatment of stage III non-small cell lung cancer (NSCLC) are still ongoing in the literature. It is important to evaluate the developments in radiotherapy and surgery along with the data in real life regarding stage III NSCLC. The aim of this study is to evaluate the treatment approaches and real-life data in stage IIIA and IIIB local advanced NSCLC.
Method: The files of 47 patients with local advanced stage IIIA and IIIB NSCLC, who were followed up in the Gazi University Faculty of Medicine, Medical Oncology Clinic between February 2016 and May 2018, were retrospectively evaluated.
Results: As the primary treatment, definitive chemoradiotherapy (CRT) to 27 (57%) patients and surgical treatment to 20 (43%) patients were applied. It was observed that the performance status (p=0.010) of the patients who underwent CRT was statistically significantly worse, active smoking (p=0.033) was higher, and had a more advanced lymph node stage (p=0.052). In the univariate analysis, it was determined that lymph node status (p=0.011), performance status of the patients (p=0.0247), and treatment modality of patients (p=0.001) were the prognostic factors affecting survival. The 1-year overall survival rates and median survival of the patients were 85% and 23 months in the surgical group respectively, and 41% and 10 months in the definitive CRT group. In the multivariate analysis, surgery was found to be a better independent prognostic factor than CRT (HR: 2.72, 95% CI: 1.27-5.82, p=0.010).
Conclusions: It was observed that the results of the patients, who were found to be respectable as a result of the clinical experience in stage III NSCLC patient group, were better. The mediastinal lymph node involvement site, especially N3 lymph node site, and the patient performance are among the important factors that determine the prognosis in stage III NSCLC.
Keywords
References
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424.
- Govindan R, Bogart J, Vokes EE. Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol. 2008;3:917–28.
- Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classifi cation of malignant tumours. J Thorac Oncol 2007; 2: 706–14.
- National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2019. Fort Washington, Pa: National Comprehensive Cancer Network, 2018.
- Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycim, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692-9.
- Shien K, Toyooka S, Kiura K, Matsuo K, Soh J, Yamane M, et al. Induction chemoradiotherapy followed by surgical resection for clinical T3 or T4 locally advanced non-small cell lung cancer. Ann Surg Oncol. 2012;19:2685–92.
- Lococo F, Cesario A, Margaritora S, Dall’Armi V, Nachira D, Cusumano G, et al. Induction therapy followed by surgery for T3-T4/N0 non-small cell lung cancer: long-term results. Ann Thorac Surg. 2012;93:1633–40.
- Toyooka S, Kiura K, Takemoto M, Oto T, Takigawa N, Fujiwara T, et al. Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 2012;14:565–9.
Details
Primary Language
English
Subjects
Health Care Administration
Journal Section
Research Article
Authors
Mukaddes Yılmaz
*
Türkiye
Birsen Yücel
Türkiye
Derya Kirman
Türkiye
Orhun Akdoğan
Türkiye
Ozan Yazıcı
Türkiye
Publication Date
March 28, 2019
Submission Date
March 15, 2019
Acceptance Date
March 26, 2019
Published in Issue
Year 2019 Volume: 41 Number: 1